Cargando…
SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433344/ https://www.ncbi.nlm.nih.gov/pubmed/36272849 http://dx.doi.org/10.1016/j.urolonc.2022.08.014 |
_version_ | 1784780612777803776 |
---|---|
author | Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj |
author_facet | Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj |
author_sort | Mungmunpuntipantip, Rujittika |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9433344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94333442022-09-01 SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj Urol Oncol Letter to Editor Elsevier Inc. 2022-12 2022-09-01 /pmc/articles/PMC9433344/ /pubmed/36272849 http://dx.doi.org/10.1016/j.urolonc.2022.08.014 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Letter to Editor Mungmunpuntipantip, Rujittika Wiwanitkit, Viroj SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence |
title | SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence |
title_full | SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence |
title_fullStr | SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence |
title_full_unstemmed | SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence |
title_short | SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence |
title_sort | sars-cov-2 mrna vaccination, prostate cancer and steroids: correspondence |
topic | Letter to Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433344/ https://www.ncbi.nlm.nih.gov/pubmed/36272849 http://dx.doi.org/10.1016/j.urolonc.2022.08.014 |
work_keys_str_mv | AT mungmunpuntipantiprujittika sarscov2mrnavaccinationprostatecancerandsteroidscorrespondence AT wiwanitkitviroj sarscov2mrnavaccinationprostatecancerandsteroidscorrespondence |